Paranoid psychosis and myoclonus: Flecainide toxicity in renal failure

Cardiology

Volumn 111, Issue 2, 2008, Pages 83-86

  Ting, Stephen M S ^a,c   Lee, Douglas ^b   Maclean, Douglas ^a   Sheerin, Neil S ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b 206 Carnegie Center   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Central nervous system toxicity; Flecainide

Indexed keywords

FLECAINIDE;

ADULT; BRAIN; CASE REPORT; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LABORATORY TEST; MYOCLONUS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANOID PSYCHOSIS; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLECAINIDE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MYOCLONUS; PARANOID DISORDERS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RISK ASSESSMENT;

EID: 50849136795     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119694     Document Type: Review

References (17)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307-1315.
3. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, Hallan HA, Lydersen S, Holmen J: International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006;17:2275-2284.
4. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406-412.
5. Bennett MI: Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. Pain 1997;70:93-94.
6. Ramhamadany E, Mackenzie S, Ramsdale DR: Dysarthria and visual hallucinations due to flecainide toxicity. Postgrad Med J 1986;62:61-62.
7. Kennedy A, Thomas P, Sheridan DJ: Generalised seizures as the presentation of flecainide toxicity. Eur Heart J 1989;10:950-954.
8. Ghika J, Goy JJ, Naegeli C, Regli F: Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy. Schweiz Arch Neurol Psychiatr 1994;145:4-6.
9. Martindale: The complete drug reference. Micromedex® Healthcare Series, 2005.
10. Sangrador G, Sanchez-Alcaraz A, Rodriguez M, Ibanez P: Clinical pharmacokinetics of intravenous flecainide in critically ill patients. J Clin Pharm Ther 1989;14:309-314.
11. Forland SC, Cutler RE, McQuinn RL, Kvam KC, Miller AM, Conard GJ, Parish S: Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. J Clin Pharmacol 1988;28:727-735.
12. William AJ, Mc Quinn RL, Walls J: Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin Pharmacol Ther 1988;43:449-455.
13. Braun J, Kollert JR, Becker JU: Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function. Eur J Clin Pharmacol 1987;31:711-714.
14. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F: Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988;44:431-435.
15. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE: Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991;50:308-313.
16. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-397 (erratum published in Clin Pharmacol Ther 1994;55:648).
17. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I: Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003;74:70-76.